

# Breast Cancer<sup>®</sup>

U P D A T E

An Audio Review Journal for Nurses

Management of Breast Cancer in the Adjuvant and Metastatic Settings

**EDITOR**

Neil Love, MD

**INTERVIEWS**

Lee S Schwartzberg, MD

Karen Dow Meneses, PhD, FAAN, RN

Rowan T Chlebowski, MD, PhD

*Additional comments from a woman  
with metastatic breast cancer  
and her best friend*



## A Continuing Nursing Education Audio Series

### STATEMENT OF NEED/TARGET AUDIENCE

Medical oncology, particularly breast cancer, is one of the most rapidly advancing and developing fields of medicine. The constant emergence of new systemic agents, new indications for existing systemic agents, novel therapies, clinical trials and research findings demands that oncology nurses remain dedicated to continuing education in order to offer their patients the best care possible. This program provides registered nurses access to the most up-to-date research developments in breast cancer and the opinions of oncology nurses and clinical investigators with experience and expertise in the field. This information can be effectively translated into everyday patient management decisions.

### PURPOSE STATEMENT

To present the most current research developments in breast cancer and to provide the perspectives of medical oncologists, oncology nurses and patients on the diagnosis and treatment of breast cancer.

### EDUCATIONAL OBJECTIVES FOR THIS ISSUE OF *BREAST CANCER UPDATE FOR NURSES*

- Discuss the clinical implications of emerging clinical trial data in breast cancer treatment and how to incorporate these data into management strategies in the adjuvant, neoadjuvant and metastatic settings.
- Discuss the selection and sequencing of endocrine therapy in the adjuvant and metastatic settings.
- Describe the risks and benefits of chemotherapeutic agents and regimens in the adjuvant and metastatic settings.
- Describe the computerized risk models and genetic markers to determine prognostic information on the quantitative risk of breast cancer relapse.
- Explain the risks and benefits of incorporating biologic agents in the adjuvant and metastatic settings.
- Discuss psychosocial and emotional needs of caregivers, patients and their loved ones associated with the diagnosis and treatment of breast cancer.

### ACCREDITATION STATEMENTS

This educational activity for 2.75 contact hours is provided by Research To Practice during the period of October 2007 through October 2008.

Research To Practice is an approved provider of continuing nursing education by the New Jersey State Nurses Association, Provider Number P215-01/07-10. NJSNA is accredited by the ANCC Commission on Accreditation. Provider Approval is valid through January 31, 2010.

### HOW TO USE THIS CNE ACTIVITY

This is an audio CNE program. This book contains CNE information, including learning objectives, faculty disclosures, a Post-test and an Evaluation Form. The corresponding website [BreastCancerUpdate.com/Nurses](http://BreastCancerUpdate.com/Nurses) also includes links to relevant abstracts and full-text articles.

The Post-test and Evaluation Form may be completed in this book and either mailed to Research To Practice, 2 South Biscayne Blvd, Suite 3600, Miami, FL 33131 or faxed to (800) 447-4310. They may also be completed online. A statement of credit will be issued only upon receipt of a completed Post-test with a score of 70 percent or better and a completed Evaluation Form. Your statement of credit will be mailed to you within three weeks or may be printed online.

*This program is supported by education grants from Abraxis BioScience, AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Genomic Health Inc and Sanofi-Aventis.*

If you would like to discontinue your complimentary subscription to *Breast Cancer Update for Nurses*, please email us at [Info@ResearchToPractice.com](mailto:Info@ResearchToPractice.com), call us at (800) 648-8654 or fax us at (305) 377-9998. Please include your full name and address, and we will remove you from the mailing list.

## Breast Cancer®

U P D A T E

## EDITOR

**Neil Love, MD**

Medical Oncologist  
Editor, *Breast Cancer Update for Nurses*  
Research To Practice  
Miami, Florida

## FACULTY

**Lee S Schwartzberg, MD**

Medical Director  
The West Clinic  
Clinical Professor of Medicine  
University of Tennessee  
School of Medicine  
Memphis, Tennessee

**Rowan T Chlebowski, MD, PhD**

Professor of Medicine  
David Geffen School of Medicine at UCLA  
Chief, Division of Medical Oncology  
and Hematology  
Harbor-UCLA Medical Center  
Torrance, California

**Karen Dow Meneses, PhD, FAAN, RN**

Professor and Associate Dean for Research  
School of Nursing  
University of Alabama at Birmingham  
Birmingham, Alabama

## CONTENT VALIDATION AND DISCLOSURES

Research To Practice is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Real or apparent conflicts of interest are identified and resolved by a peer review content validation process. The content of each activity is reviewed by both a member of the scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

The scientific staff and consultants for Research To Practice are involved in the development and review of content for educational activities and report the following real or apparent conflicts of interest, either current or within the past 12 months, for themselves (or their spouses/partners) that have been resolved through a peer review process:

Lisa Aiello-Laws RN, MSN, APN,C, AOCNS, Richard Kaderman, PhD, Joanne Librie, RN, Neil Love, MD, Douglas Paley, Margaret Peng, Lilliam Sklaver Poltorack, PharmD, Erin Wall and Kathryn Ault Ziel, PhD — no real or apparent conflicts of interest to report; Aviva Asnis-Alibozek, PA-C, MPAS — salary: AstraZeneca Pharmaceuticals LP; shareholder of AstraZeneca Pharmaceuticals LP; Sally Bogert, RNC, WHCNP — shareholder of Amgen Inc and Genentech BioOncology; Anne O'Connor, RN, MSN, AOCN — shareholder of Abraxis BioScience. Research To Practice receives education grants from Abraxis BioScience, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Biogen Idec, Genentech BioOncology/OSI Pharmaceuticals Inc, Genomic Health Inc, GPC Biotech, Roche Laboratories Inc and Sanofi-Aventis, who have no influence on the content development of our educational activities.

In addition, the following faculty (and their spouses/partners) have reported real or apparent conflicts of interest that have been resolved through a peer review process:

**Dr Schwartzberg** — Speaker/Speakers Bureau: Amgen Inc, Genentech BioOncology, GlaxoSmithKline. **Dr Meneses** — Research Support: National Cancer Institute; **Speaker/Speakers Bureau:** Novartis Pharmaceuticals Corporation. **Dr Chlebowski** — Consultant: AstraZeneca Pharmaceuticals LP, Eli Lilly and Company, Novartis Pharmaceuticals Corporation, Organon, Sanofi-Aventis; Research Support: Eli Lilly and Company, Organon; **Speaker/Speakers Bureau:** AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Novartis Pharmaceuticals Corporation.

*This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.*

**Breast Cancer Update for Nurses — Issue 5, 2007****QUESTIONS (PLEASE CIRCLE ANSWER):**

- 1. A Phase \_\_\_\_\_ clinical trial is always randomized and compares a new drug or regimen to the current standard treatment.**
  - a. I
  - b. II
  - c. III
- 2. Premedicating patients with antihistamines and/or dexamethasone to avoid hypersensitivity reactions \_\_\_\_\_ required when administering *nab* paclitaxel.**
  - a. Is
  - b. Is not
- 3. In the TAILORx study, patients with an intermediate recurrence score as determined by the *Oncotype DX*™ assay are randomly assigned to receive endocrine therapy with or without \_\_\_\_\_.**
  - a. Chemotherapy
  - b. Bevacizumab
  - c. Trastuzumab
- 4. In a clinical trial that compared doxorubicin/cyclophosphamide (AC) to docetaxel/cyclophosphamide (TC) in the adjuvant setting, which of the regimens was more efficacious?**
  - a. AC
  - b. TC
- 5. Potential side effects associated with the use of docetaxel include which of the following?**
  - a. Lacrimal drainage obstruction
  - b. Neurotoxicity
  - c. Nail changes
  - d. All of the above
- 6. Which endocrine agent is administered by intramuscular injection?**
  - a. Anastrozole
  - b. Exemestane
  - c. Fulvestrant
  - d. Tamoxifen
- 7. The ATAC trial, comparing adjuvant tamoxifen to anastrozole, demonstrated a lower incidence of strokes among patients treated with \_\_\_\_\_.**
  - a. Anastrozole
  - b. Tamoxifen
- 8. NSABP-B-40 is a Phase III, randomized study of neoadjuvant chemotherapy with or without neoadjuvant and adjuvant \_\_\_\_\_ in women with early breast cancer.**
  - a. Anastrozole
  - b. Bevacizumab
  - c. Tamoxifen
  - d. Trastuzumab
- 9. Which of the following endocrine therapies can cause menopausal symptoms such as hot flashes?**
  - a. Anastrozole
  - b. Letrozole
  - c. Exemestane
  - d. Tamoxifen
  - e. a, b and c
  - f. All of the above
- 10. Clinical trials have reported that adjuvant trastuzumab administered to a patient with HER2-positive breast cancer reduces the patient's risk of recurrence by approximately \_\_\_\_\_.**
  - a. 10 percent
  - b. 20 percent
  - c. 30 percent
  - d. 50 percent
  - e. 90 percent

## EVALUATION FORM

### *Breast Cancer Update for Nurses — Issue 5, 2007*

Research To Practice respects and appreciates your opinions. To assist us in evaluating the effectiveness of this activity and to make recommendations for future educational offerings, please take a few minutes to complete this Evaluation Form. A statement of credit will be issued only upon receipt of a completed Evaluation Form and a completed Post-test with a score of 70 percent or better.

**Please answer the following questions by circling the appropriate rating:**

5 =  
Outstanding

4 =  
Good

3 =  
Satisfactory

2 =  
Fair

1 =  
Poor

#### EXTENT TO WHICH PROGRAM ACTIVITIES MET THE IDENTIFIED GOAL

- To present the most current research developments in breast cancer and to provide the perspectives of medical oncologists, oncology nurses and patients on the diagnosis and treatment of breast cancer. . . . . 5 4 3 2 1

#### EXTENT TO WHICH PROGRAM ACTIVITIES MET THE IDENTIFIED OBJECTIVES

**Upon completion of this activity, participants should be better able to:**

- Discuss the clinical implications of emerging clinical trial data in breast cancer treatment and how to incorporate these data into management strategies in the adjuvant, neoadjuvant and metastatic settings. . . . . 5 4 3 2 1
- Discuss the selection and sequencing of endocrine therapy in the adjuvant and metastatic settings. . . . . 5 4 3 2 1
- Describe the risks and benefits of chemotherapeutic agents and regimens in the adjuvant and metastatic settings. . . . . 5 4 3 2 1
- Describe the computerized risk models and genetic markers to determine prognostic information on the quantitative risk of breast cancer relapse. . . . . 5 4 3 2 1
- Explain the risks and benefits of incorporating biologic agents in the adjuvant and metastatic settings. . . . . 5 4 3 2 1
- Discuss psychosocial and emotional needs of caregivers, patients and their loved ones associated with the diagnosis and treatment of breast cancer. . . . . 5 4 3 2 1

#### EFFECTIVENESS OF THE INDIVIDUAL FACULTY MEMBERS

Faculty	Knowledge of subject matter	Effectiveness as an educator
Lee S Schwartzberg, MD	5 4 3 2 1	5 4 3 2 1
Karen Dow Meneses, PhD, FAAN, RN	5 4 3 2 1	5 4 3 2 1
Rowan T Chlebowski, MD, PhD	5 4 3 2 1	5 4 3 2 1

#### OVERALL EFFECTIVENESS OF THE ACTIVITY

- Will assist me in improving patient care. . . . . 5 4 3 2 1
- Fulfilled my educational needs. . . . . 5 4 3 2 1
- Avoided commercial bias or influence. . . . . 5 4 3 2 1

#### IMPACT OF THE ACTIVITY

**The information presented (check all that apply):**

- Reinforced my current practice/treatment habits.
- Enhanced my current knowledge base.

EVALUATION FORM

Breast Cancer Update for Nurses — Issue 5, 2007

IMPACT OF THE ACTIVITY (CONTINUED)

Will the information presented cause you to make any changes in your practice?

- Yes No

If yes, please describe any change(s) you plan to make in your practice as a result of this activity:

If yes, how committed are you to making these changes?

(5 = very committed; 1 = not at all committed) 5 4 3 2 1

FUTURE ACTIVITIES

Do you feel future activities on this subject matter are necessary and/or important to your practice?

- Yes No

Please list any other topics that would be of interest to you for future educational activities:

Additional comments about this activity:

FOLLOW-UP

As part of our ongoing, continuous quality-improvement effort, we conduct postactivity follow-up surveys to assess the impact of our educational interventions on professional practice. Please indicate your willingness to participate in such a survey:

- Yes, I am willing to participate in a follow-up survey. No, I am not willing to participate in a follow-up survey.

REQUEST FOR CREDIT — please print clearly

Name: Degree: Organization: Specialty: Address: City, State, Zip: Telephone: Fax: Email: Signature: Date:

Which of the following audio formats of this program did you use?

- Audio CDs Downloaded MP3s from website

To obtain credit, complete the Post-test and Evaluation Form and mail to Research To Practice, 2 South Biscayne Blvd, Suite 3600, Miami, FL 33131, fax to (800) 447-4310 or complete both online. A statement of credit will be issued only upon receipt of a completed Post-test with a score of 70 percent or better and a completed Evaluation Form. Your statement of credit will be mailed to you within three weeks or may be printed online.

BCUN407

# Breast Cancer®

U P D A T E

<b>Editor/CME Director</b>	Neil Love, MD
<b>Managing Editor</b>	Kathryn Ault Ziel, PhD
<b>Scientific Director</b>	Richard Kaderman, PhD
<b>Senior Director, Medical Affairs</b>	Aviva Asnis-Alibozek, PA-C, MPAS
<b>Writers</b>	Lilliam Sklaver Poltorack, PharmD Douglas Paley
<b>Continuing Education Administrator for Nursing</b>	Sally Bogert, RNC, WHCNP
<b>Content Validation</b>	Margaret Peng Erin Wall
<b>Director, Creative and Copy Editing</b>	Aura Herrmann
<b>Creative Manager</b>	Fernando Rendina
<b>Graphic Designers</b>	Jason Cunniss Tamara Dabney Shantia Daniel Elisa Stambouli
<b>Senior Production Editor</b>	Alexis Oneca
<b>Traffic Manager</b>	Tere Sosa
<b>Copy Editors</b>	Dave Amber Margo Harris David Hill Rosemary Hulce Kirsten Miller Pat Morrissey/Havlin Carol Peschke Susan Petrone
<b>Production Manager</b>	Rena Chiarelli
<b>Audio Production</b>	Frank Cesarano
<b>Web Master</b>	John Ribeiro
<b>Faculty Relations Manager</b>	Melissa Vives
<b>Contact Information</b>	Neil Love, MD Research To Practice One Biscayne Tower 2 South Biscayne Boulevard, Suite 3600 Miami, FL 33131 Fax: (305) 377-9998 Email: <a href="mailto:DrNeilLove@ResearchToPractice.com">DrNeilLove@ResearchToPractice.com</a> Email: <a href="mailto:CNE@ResearchToPractice.com">CNE@ResearchToPractice.com</a>
<b>For CNE Information</b>	

Copyright © 2007 Research To Practice. All rights reserved.

The compact discs, Internet content and accompanying printed material are protected by copyright. No part of this program may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording or utilizing any information storage and retrieval system, without written permission from the copyright owner.

The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their

own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.

Any procedures, medications or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information and comparison with recommendations of other authorities.

# Breast Cancer<sup>®</sup>

U P D A T E

Copyright © 2007 Research To Practice.

This program is supported by education grants from Abraxis BioScience, AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Genomic Health Inc and Sanofi-Aventis.



Sponsored by Research To Practice.

Last review date: October 2007

Release date: October 2007

Expiration date: October 2008

Contact hours: 2.75